Citation

Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. Brain Res. 1995; 681(1-2): 109-116.

Copyright

(Copyright © 1995, International Brain Research Organization, Publisher Elsevier Publishing)

DOI

10.1016/0006-8993(95)00301-6

PMID

7552267

Abstract

The densities of dopamine-D4 receptors were determined in postmortem samples of caudate nucleus from patients with schizophrenia (n = 9) and age-matched controls (n = 10). D4 receptor binding was defined as the difference between binding sites labeled by [3H]YM-09151-2 (D2 + D3 + D4 receptors) and those by [3H]raclopride, in the presence of 5'-guanylylimidodiphosphate (Gpp(NH)p) (D2 + D3 receptors). D4 receptor binding was measurable in all the subjects with schizophrenia (mean = 3.8 pmol/g tissue) but only in 3/10 controls. To determine the specificity of these findings for schizophrenia, D4 receptor binding was also measured in the caudate nucleus of suicide victims with major depression (n = 6) and age-matched controls (n = 6). A small amount of D4 binding was noted in some of the controls + depressed subjects and there was no significant difference between controls and patients with major depression. The addition of 200 microM Gpp(NH)p to the assay significantly increased the amount of specific binding of [3H]raclopride in control tissues, but not in tissues from subjects with schizophrenia, suggesting an abnormality in the G-protein component coupled to the D2 receptor. [3H]Raclopride binding was also significantly increased by Gpp(NH)p in subjects with major depression. These results confirm a previous report of Seeman et al. (1993) and suggest that measurable D4 receptor binding in the caudate nucleus is more frequent in patients with schizophrenia as compared with normal controls and subjects with major depression and that guanine nucleotides do not enhance [3H]raclopride binding in schizophrenia.(ABSTRACT TRUNCATED AT 250 WORDS)

Language: en

Keywords

Adult; Aged; Aged, 80 and over; Benzamides; Caudate Nucleus; Depressive Disorder; Dopamine Antagonists; Female; GTP-Binding Proteins; Guanine Nucleotides; Guanylyl Imidodiphosphate; Humans; In Vitro Techniques; Kinetics; Male; Middle Aged; Raclopride; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D4; Salicylamides; Schizophrenia